Drugs / GW784568X
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00404586 | Sep 2006 → Jan 2007 | perennial allergic rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GW784568X | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00404586 ↗ |
| Route | Intranasal | “GW784568X will be delivered as a micronized suspension (50 or 100mcg/spray) via an aqueous nasal spray.” NCT00404586 ↗ |